📣 VC round data is live. Check it out!

Pangaea Oncology Valuation Multiples

Discover revenue and EBITDA valuation multiples for Pangaea Oncology and similar public comparables like Tobii, Spectral AI, Xtant Medical, Meta Biomed and more.

Pangaea Oncology Overview

About Pangaea Oncology

Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.


Founded

2007

HQ

Spain

Employees

53

Financials (FY)

Revenue: $17M
EBITDA: ($1M)

EV

$69M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Pangaea Oncology Financials

Pangaea Oncology reported last fiscal year revenue of $17M and negative EBITDA of ($1M).

In the same fiscal year, Pangaea Oncology generated $17M in gross profit, ($1M) in EBITDA losses, and had net loss of ($4M).


Pangaea Oncology P&L

In the most recent fiscal year, Pangaea Oncology reported revenue of $17M and EBITDA of ($1M).

Pangaea Oncology is unprofitable as of last fiscal year, with gross margin of 99%, EBITDA margin of (7%), and net margin of (25%).

See analyst estimates for Pangaea Oncology
Last FY202320242025202620272028
Revenue$17M$9M$17M$17M
Gross Profit$17M$9M$17M$17M
Gross Margin99%97%100%99%
EBITDA($1M)($2M)$1M($1M)
EBITDA Margin(7%)(19%)8%(7%)
EBIT Margin(25%)(34%)(14%)(25%)
Net Profit($4M)($5M)($1M)($4M)
Net Margin(25%)(58%)(8%)(25%)
Net Debt$4M---

Financial data powered by Morningstar, Inc.

Pangaea Oncology Stock Performance

Pangaea Oncology has current market cap of $66M, and enterprise value of $69M.

Market Cap Evolution


Pangaea Oncology's stock price is $1.84.

Pangaea Oncology share price decreased by 0.2% in the last 30 days, and by 5.6% in the last year.

Pangaea Oncology has an EPS (earnings per share) of $-0.12.

See more trading valuation data for Pangaea Oncology
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$69M$66M-0.1%-0.2%-3.7%-5.6%$-0.12

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Pangaea Oncology Valuation Multiples

Pangaea Oncology trades at 4.1x EV/Revenue multiple, and (62.9x) EV/EBITDA.

See NTM and 2027E valuation multiples for Pangaea Oncology

Pangaea Oncology Financial Valuation Multiples

As of June 3, 2026, Pangaea Oncology has market cap of $66M and EV of $69M.

Pangaea Oncology has a P/E ratio of (15.8x).

Last FY202320242025202620272028
EV/Revenue4.1x7.4x4.2x4.1x
EV/EBITDA(62.9x)(38.2x)50.2x(62.9x)
EV/EBIT(16.3x)(21.7x)(29.8x)(16.3x)
EV/Gross Profit4.1x7.7x4.2x4.1x
P/E(15.8x)(12.2x)(48.6x)(15.8x)
EV/FCF(19.9x)(22.1x)(11.7x)(19.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Pangaea Oncology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Pangaea Oncology Margins & Growth Rates

In the most recent fiscal year, Pangaea Oncology reported gross margin of 99%, EBITDA margin of (7%), and net margin of (25%).

See estimated margins and future growth rates for Pangaea Oncology

Pangaea Oncology Margins

Last FY20242025202720282029
Gross Margin99%100%99%
EBITDA Margin(7%)8%(7%)
EBIT Margin(25%)(14%)(25%)
Net Margin(25%)(8%)(25%)
FCF Margin(21%)(36%)(21%)

Pangaea Oncology Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth78%2%
Gross Profit Growth84%1%
EBITDA Growth(176%)(180%)
EBIT Growth(27%)83%
Net Profit Growth(75%)208%
FCF Growth89%(41%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Pangaea Oncology Operational KPIs

Pangaea Oncology's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.

Access forward-looking KPIs for Pangaea Oncology
Last FY202320242025202620272028
Revenue per Employee$0.3M---
Opex per Employee$0.4M---
S&M Expenses to Revenue1%2%1%1%
G&A Expenses to Revenue31%39%29%31%
Opex to Revenue124%131%114%124%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Pangaea Oncology Competitors

Pangaea Oncology competitors include Tobii, Spectral AI, Xtant Medical, Meta Biomed, Susmed, Meditera, Pulmonx, Theraclion, Osang Healthcare and SMAIO.

Most Pangaea Oncology public comparables operate across Diagnostics & Genomics, Medical Devices, BioTech, DeepTech, B2B SaaS, Vertical SaaS, HealthTech and Longevity.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Tobii1.3x1.4x3.5x4.6x
Spectral AI3.3x3.3x(14.1x)-
Xtant Medical0.5x0.6x4.3x7.2x
Meta Biomed1.0x-5.0x-
Susmed12.7x12.7x(21.8x)-
Meditera0.9x-12.1x-
Pulmonx0.7x0.7x(1.8x)(1.9x)
Theraclion67.2x-(9.5x)-

This data is available for Pro users. Sign up to see all Pangaea Oncology competitors and their valuation data.

Start Free Trial

Pangaea Oncology VC Funding History

Before going public, Pangaea Oncology raised $12M in total equity funding, across 1 round.


Pangaea Oncology Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jul-22Series A-$12M-Pangaea Oncology is a Spain-based biotechnology company focused on precision oncology and personalized medicine through genetic analyses, operating in clinical care at the Dr. Rosell Oncology Institute and molecular diagnostics including liquid biopsy and multiplexing. The company announced a private placement of 2,500,000 shares at €1.55 per share, expecting gross proceeds of €3.875 million on May 13, 2022, subject to shareholder approval in June 2022.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Pangaea Oncology

When was Pangaea Oncology founded?Pangaea Oncology was founded in 2007.
Where is Pangaea Oncology headquartered?Pangaea Oncology is headquartered in Spain.
How many employees does Pangaea Oncology have?As of today, Pangaea Oncology has over 53 employees.
Is Pangaea Oncology publicly listed?Yes, Pangaea Oncology is a public company listed on Bolsa de Madrid.
What is the stock symbol of Pangaea Oncology?Pangaea Oncology trades under PANG ticker.
When did Pangaea Oncology go public?Pangaea Oncology went public in 2016.
Who are competitors of Pangaea Oncology?Pangaea Oncology main competitors include Tobii, Spectral AI, Xtant Medical, Meta Biomed, Susmed, Meditera, Pulmonx, Theraclion, Osang Healthcare, SMAIO.
What is the current market cap of Pangaea Oncology?Pangaea Oncology's current market cap is $66M.
What is the current revenue of Pangaea Oncology?Pangaea Oncology's last fiscal year revenue is $17M.
What is the current EV/Revenue multiple of Pangaea Oncology?Current revenue multiple of Pangaea Oncology is 4.1x.
Is Pangaea Oncology profitable?No, Pangaea Oncology is not profitable.
How many companies Pangaea Oncology has acquired to date?Pangaea Oncology hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Pangaea Oncology has invested to date?Pangaea Oncology hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Pangaea Oncology

Lists including Pangaea Oncology

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial